Insider · CIK 0001656026
Edward Andrle
Files at NMTC (NEUROONE MEDICAL TECHNOLOGIES Corp). First filing -, latest -.
Edward Andrle files SEC Form 4 as director at NMTC (NEUROONE MEDICAL TECHNOLOGIES Corp). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Edward Andrle has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 3, 2026 | NMTC NEUROONE MEDICAL TECHNOLOGIES Corp | AGrant or award Common Stock | +41,929 | $0.00 | $0 | 133,932 | Apr 7, 2026 |
| Apr 3, 2026 | NMTC NEUROONE MEDICAL TECHNOLOGIES Corp | AGrant or award Option to Purchase Common Stockderivative | +26,036 | $0.00 | $0 | 26,036 | Apr 7, 2026 |
| Jun 23, 2025 | NMTC NEUROONE MEDICAL TECHNOLOGIES Corp | AGrant or award Option to Purchase Common Stockderivative | +50,000 | $0.00 | $0 | 50,000 | Jun 25, 2025 |
| Feb 14, 2025 | NMTC NEUROONE MEDICAL TECHNOLOGIES Corp | AGrant or award Common Stock | +27,778 | $0.00 | $0 | 92,003 | Feb 19, 2025 |
| Feb 14, 2025 | NMTC NEUROONE MEDICAL TECHNOLOGIES Corp | AGrant or award Option to Purchase Common Stockderivative | +17,025 | $0.00 | $0 | 17,025 | Feb 19, 2025 |
Questions about Edward Andrle
Answered from the filings on this page, as of the latest one.
Is Edward Andrle buying or selling?
Edward Andrle has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Edward Andrle's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Edward Andrle has 0.
Where does Edward Andrle file Form 4?
Edward Andrle has filed Form 4 at NMTC (NEUROONE MEDICAL TECHNOLOGIES Corp). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.